+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Mucinous cystic neoplasm - Pipeline Insight, 2021

  • ID: 5261997
  • Drug Pipelines
  • February 2021
  • Region: Global
  • 60 pages
  • DelveInsight
1 of 3

FEATURED COMPANIES

  • Biophytis
  • Eli Lily
  • Immunoforge
  • Novartis
  • MORE
This “Mucinous cystic neoplasm - Pipeline Insight, 2021,” report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Mucinous cystic neoplasm pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered
  • Global coverage
Mucinous cystic neoplasm Understanding

Mucinous cystic neoplasm: Overview

Mucinous cystic neoplasm are the rare tumors of pancreas, situated in the body or tail of pancreas. This type of neoplasm mostly occurs in middle-aged female. These neoplasms are usually large, septate, thick-walled mucinous cysts that lack communication with ductal system. There are two different histological components of mucinous cystic neoplasm, which are the inner-epithelial layer composed of tall mucin secreting cells and dense cellular ovarian stroma. These neoplasms rarely metastasize but if left untreated can become cancerous. The exact cause for mucinous cystic neoplasm is still unknown. People with gallstones, pancreatitis, and pseudocyst are likely to develop mucinous cystic neoplasm. Jaundice is evident in the people with pancreatic head mucinous cystic neoplasm.

"Mucinous cystic neoplasm - Pipeline Insight, 2021" report outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Mucinous cystic neoplasm pipeline landscape is provided which includes the disease overview and Mucinous cystic neoplasm treatment guidelines. The assessment part of the report embraces, in depth Mucinous cystic neoplasm commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Mucinous cystic neoplasm collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights
  • The companies and academics are working to assess challenges and seek opportunities that could influence Mucinous cystic neoplasm R&D. The therapies under development are focused on novel approaches to treat/improve Mucinous cystic neoplasm
Mucinous cystic neoplasm Emerging Drugs Chapters

This segment of the Mucinous cystic neoplasm report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Mucinous cystic neoplasm Emerging Drugs
  • Sarconeos (BIO101): Biophytis
Biophytis’ lead drug candidate, Sarconeos (BIO101), is an orally administered small molecule in development for the treatment of neuromuscular diseases. Preclinical data demonstrated that Sarconeos (BIO101) for the treatment of mucinous cystic neoplasm has beneficial effects on muscle function and increases muscle strength and mobility in animal models. It activates the MAS receptor in muscle cells, a key component of the Renin-Angiotensin System (RAS).
  • Bimagrumab: Novartis
Novartis “breakthrough” drug bimagrumab is currently being evaluated for the treatment of mucinous cystic neoplasm and has demonstrated good safety and efficacy profile in phase III trials. Bimagrumab is a human monoclonal antibody that binds to type II activin receptors and prevents the binding of its ligands (e.g., myostatin, activin A). These ligands normally act as inhibitors of muscle growth and protein anabolism; bimagrumab lifts this inhibition and can increase muscle mass in young and older adults.

Mucinous cystic neoplasm: Therapeutic Assessment

This segment of the report provides insights about the different Mucinous cystic neoplasm drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Mucinous cystic neoplasm

There are approx. 10+ key companies which are developing the therapies for Mucinous cystic neoplasm. The companies which have their Mucinous cystic neoplasm drug candidates in the mid to advanced stage, i.e. phase III and Phase II include, Novartis and others.

The report covers around 10+ products under different phases of clinical development like
  • Mid-stage products (Phase II and Phase I/II)
  • Early-stage products (Phase I/II and Phase I) along with the details of
  • Pre-clinical and Discovery stage candidates
  • Discontinued & Inactive candidates
  • Route of Administration
Mucinous cystic neoplasm pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
  • Subcutaneous
  • Intravenous
  • Oral
  • Intramuscular
  • Molecule Type
Products have been categorized under various Molecule types such as
  • Small molecules
  • Natural metabolites
  • Monoclonal antibodies
  • Product Type
The drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Mucinous cystic neoplasm: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Mucinous cystic neoplasm therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Mucinous cystic neoplasm drugs.

Mucinous cystic neoplasm Report Insights
  • Mucinous cystic neoplasm Pipeline Analysis
  • Therapeutic Assessment
  • Unmet Needs
  • Impact of Drugs
Mucinous cystic neoplasm Report Assessment
  • Pipeline Product Profiles
  • Therapeutic Assessment
  • Pipeline Assessment
  • Inactive drugs assessment
  • Unmet Needs
Key Questions Answered

Current Treatment Scenario and Emerging Therapies:
  • How many companies are developing Mucinous cystic neoplasm drugs?
  • How many Mucinous cystic neoplasm drugs are developed by each company?
  • How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Mucinous cystic neoplasm?
  • What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Mucinous cystic neoplasm therapeutics?
  • What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
  • What are the clinical studies going on for Mucinous cystic neoplasm and their status?
  • What are the key designations that have been granted to the emerging drugs?
Key Players
  • Biophytis
  • Novartis
  • Eli Lily
  • Regeneron Pharmaceuticals/ Sanofi
  • Immunoforge
Key Products
  • Sarconeos
  • Bimagrumab
  • LY2495655
  • Trevogrumab
  • PF 1801
Note: Product cover images may vary from those shown
2 of 3

FEATURED COMPANIES

  • Biophytis
  • Eli Lily
  • Immunoforge
  • Novartis
  • MORE
Introduction

Executive Summary

Mucinous cystic neoplasm: Overview
  • Causes
  • Mechanism of Action
  • Signs and Symptoms
  • Diagnosis
  • Disease Management
Pipeline Therapeutics
  • Comparative Analysis
Therapeutic Assessment
  • Assessment by Product Type
  • Assessment by Stage and Product Type
  • Assessment by Route of Administration
  • Assessment by Stage and Route of Administration
  • Assessment by Molecule Type
  • Assessment by Stage and Molecule Type
Mucinous cystic neoplasm - Analytical Perspective

In-depth Commercial Assessment
  • Mucinous cystic neoplasm companies' collaborations, Licensing, Acquisition - Deal Value Trends
Mucinous cystic neoplasm Collaboration Deals
  • Company-Company Collaborations (Licensing / Partnering) Analysis
  • Company-University Collaborations (Licensing / Partnering) Analysis
Late Stage Products (Phase III)
  • Comparative Analysis
Bimagrumab: Novartis
  • Product Description
  • Research and Development
  • Product Development Activities
Mid Stage Products (Phase II)
  • Comparative Analysis
BIO101: Biophytis
  • Product Description
  • Research and Development
  • Product Development Activities
Pre-clinical and Discovery Stage Products
  • Comparative Analysis
  • Product Description
  • Research and Development
  • Product Development Activities
Inactive Products
  • Comparative Analysis
Mucinous cystic neoplasm Key Companies

Mucinous cystic neoplasm Key Products

Mucinous cystic neoplasm - Unmet Needs

Mucinous cystic neoplasm - Market Drivers and Barriers

Mucinous cystic neoplasm - Future Perspectives and Conclusion

Mucinous cystic neoplasm Analyst Views

Mucinous cystic neoplasm Key Companies

Appendix

List of Tables
Table 1 Total Products for Mucinous cystic neoplasm
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products

List of Figures
Figure 1 Total Products for Mucinous cystic neoplasm
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
Note: Product cover images may vary from those shown
3 of 3
  • Biophytis
  • Novartis
  • Eli Lily
  • Regeneron Pharmaceuticals/ Sanofi
  • Immunoforge
Note: Product cover images may vary from those shown
Adroll
adroll